In pulmonary fibrosis, healthy lung tissue is gradually replaced by scar. The cells behind it are fibroblasts, which are connective tissue cells that normally sit quietly and maintain the supporting framework of the lung. Once they switch into a state called the myofibroblast, they begin to contract, invade the surrounding tissue and secrete large amounts of extracellular matrix, leaving the lung stiffer and less able to expand and to take up oxygen. What pushes a healthy fibroblast to make that switch, and how it might be stopped, has remained unclear.
The Precision Regenerative Medicine (PRM) unit at Helmholtz Munich, headed by Prof. Herbert Schiller and Dr. Martin Mück-Häusl, has now identified a decisive step in this process. Working with partners at LMU Munich, the Max Planck Institute of Biochemistry and KU Leuven, co-first authors Safwen Kadri and Laura F. Mattner show that a single chemical modification on the protein NFATC4 acts as a switch that commits lung fibroblasts to the fibrotic state. The study is published in The Journal of Clinical Investigation.
Cells measure the stiffness of their surroundings
The team grew primary human lung fibroblasts on silicone gels coated with fibronectin (an ECM component of injured human tissues) engineered to match the mechanical stiffness of relaxed and contracted tissue, from very soft (0.5 kPa) to stiff (32 kPa), and used mass spectrometry to record every phosphorylation event in the cells. Phosphorylation is the addition of a phosphate group to a protein, one of the fastest ways cells relay information.
The resulting map covers more than 10,000 phosphorylation sites, including 656 that had never been described before. It revealed a sharp threshold: between 2 and 8 kPa, the cells switch behaviour. Below it they stay quiescent; above it they reorganise their cytoskeleton, ramp up matrix production and take on the myofibroblast identity. Healthy lung tissue sits at roughly 1-5 kPa, just below the threshold, while fibrotic lung reaches 10-50 kPa which is well above homeostasis.
One switch, both directions
Among the proteins responding to stiffness, the transcription factor NFATC4 stood out, modified at two specific positions, S213 and S217. Analysis of a multi-cohort single-cell atlas of pulmonary fibrosis patients confirmed that NFATC4 is unusually active in fibroblasts, controlling a core programme of 119 genes. Its most prominent target, CTHRC1, is a well defined marker of the pathogenic myofibroblasts that drive fibrosis in lung, heart and liver.
In lung tissue from patients, staged by micro-CT into mild, moderate and severe disease, NFATC4 rose steadily with disease severity and accumulated in exactly the cells carrying the myofibroblast markers.
The decisive experimental evidence came from engineering the phosphorylation switch directly. A version of NFATC4 permanently locked in the "on" position drove full myofibroblast conversion on soft matrix, without any chemical stimulation. A version that cannot be switched on blocked the conversion even on stiff matrix and with TGF-β present, which normally rapidly converts these fibroblasts into disease causing myofibroblasts. The switch is therefore both necessary and sufficient. Mechanical force and TGF-β signalling, long studied as separate routes to fibrosis, converge on it.
Consistent with this, established inhibitors of the enzymes that operate the switch, the JNK kinase and the phosphatase calcineurin, suppressed the fibrotic conversion in the primary human cell models. Calcineurin is blocked by clinically used drugs such as tacrolimus and cyclosporin A. All key findings were reproduced in fibroblasts taken from patients with idiopathic pulmonary fibrosis.
Why it matters
Fibrotic disease contributes to a large share of deaths worldwide, and treatment options remain limited. “The self-reinforcing loop between stiffening tissue and activated fibroblasts is what makes fibrosis so hard to stop,” says Prof. Schiller. “We now have a defined molecular entry point where we can try to stop that loop therapeutically.”
"Fibroblast mechanosensing is a complicated process, with hundreds of signalling events running in parallel," says Safwen Kadri, co-first author of the study. "Narrowing it down to one decisive phospho-switch makes environmental sensing something we can actually modify and opens avenues to manipulate how cells perceive tissue tension and matrix rigidity."
Because NFATC4 has also been implicated in fibrosis of the heart, liver and kidney, the authors propose the switch as a candidate target across organs. They caution that the work has been done in human cell systems and patient tissue: efficacy of therapeutic targeting will need to be tested in preclinical models before any conclusions can be drawn.
Key facts
- More than 1800 phosphorylation sites mapped in human lung fibroblasts that respond to tissue stiffness, including many regulatory sites on transcription factors.
- 8 kPa is the stiffness threshold at which fibroblasts commit to the fibrotic state.
- 119 genes in the NFATC4-controlled fibrotic programme; top target: CTHRC1.
- The NFATC4 S213/S217 switch is necessary and sufficient, and independent of TGF-β.
- Validated in patient tissue staged by micro-CT and in IPF patient-derived cells.
Original publication
Kadri S, Mattner LF, et al. Mechanosensitive phosphorylation of NFATC4 at S213/S217 drives fibroblast-to-myofibroblast transition and fibrosis. The Journal of Clinical Investigation. DOI: 10.1172/JCI195121